0.84
+10.29%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Compass Therapeutics
From its filings with the US Securities and Exchange Commission
Compass Therapeutics is based in Boston, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CMPX. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $66.5m. At that date it held total assets of $219.6m and shareholders' equity of $196.8m.
We are a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Our scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Our pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. We plan to advance our product candidates through clinical development and commercialization as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data.
Our pipeline consists of four clinical product candidates. Our lead product candidate, tovecimig (formerly known as CTX-009), is a bispecific antibody targeting Delta-like ligand 4 (“DLL4”), a ligand of Notch-1, and vascular endothelial growth factor A (“VEGF-A”). Simultaneous blockade of the VEGF-A and the Notch pathways is known to turn productive angiogenesis into non-productive angiogenesis, which leads to tumor shrinkage and apoptosis.
Quoted from its 10-K, filed 5 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 13 Nov 2020
- Employees
- 39
- Website
- compasstherapeutics.com ↗
- Head office
- 80 GUEST STREET, BOSTON, MA, 02135
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Carl GordonIndependent Chairman of the Board$110,683
- Dr. Thomas SchuetzChief Executive Officer, Vice Chairman of the Board, since 2014$3.1m
- Mr. Barry ShinChief Financial Officer$1.2m
- Mr. Neil LernerSenior Vice President, Chief Accounting Officer and Principal Accounting Officer
- Mr. Jonathan AndermanSenior Vice President, General Counsel, Corporate Secretary$893,635
- Mr. James BoylanIndependent Director$105,920
- Ms. Ellen ChiniaraIndependent Director$105,683
- Mr. Philip FerneauIndependent Director$100,683
- Dr. Mary GrayIndependent Director$91,933
- Mr. Richard LindahlIndependent Director$100,683
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 57
- Environment
- 60
- Social
- 70
- Governance
- 41
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Compass Therapeutics has a focused pipeline with three proprietary antibody therapeutics in development.
- CTX-009 targets DLL4 and VEGF-A for multiple disease treatments.
- CTX-471 is an agonistic antibody targeting CD-137 for immune system activation.
Weaknesses
- Compass Therapeutics employs only 26 full-time employees as of the latest data.
- The company's IPO occurred in November 2020 with limited market presence.
- Compass Therapeutics has no commercialized products yet in the biopharmaceutical market.
Opportunities
- The biotechnology sector in the US offers significant growth potential for clinical-stage companies.
- Compass Therapeutics' pipeline targets validated immune-oncology targets like PD-1 and PD-L1.
- The US Health Care sector continues to invest in innovative antibody therapeutics.
Threats
- Compass Therapeutics faces competition from established biopharmaceutical firms in the US market.
- The biotechnology industry is highly regulated with strict FDA approval processes.
- Compass Therapeutics must secure additional funding to advance its clinical-stage programs.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.